A Pilot Single dose Open-Label Study of OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer Comparing Camera Imaging Systems
Enrolling By Invitation
99 years or below
All
40 participants needed
1 Location
Brief description of study
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination with OTL38. This study will provide information about the suitability of other camera systems that may be used to better assess ovarian cancers targeted by OTL38.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ovarian cancer
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 830141
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
